Grifols, S.a. (GRFS)

$7.74

-0.04

(-0.51%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $7.74
    $8.07
    $7.74
    downward going graph

    0.0%

    Downside

    Day's Volatility :4.09%

    Upside

    4.09%

    downward going graph
  • $5.30
    $12.15
    $7.74
    downward going graph

    31.52%

    Downside

    52 Weeks Volatility :56.38%

    Upside

    36.3%

    downward going graph

Returns

PeriodGrifols, S.a.Sector (Health Care)Index (Russel 2000)
3 Months
21.94%
6.5%
0.0%
6 Months
-2.87%
7.1%
0.0%
1 Year
-23.65%
9.8%
0.0%
3 Years
-48.78%
14.2%
-20.2%

Highlights

Market Capitalization
6.2B
Book Value
$8.75
Earnings Per Share (EPS)
0.1
PE Ratio
77.3
PEG Ratio
0.26
Wall Street Target Price
11.97
Profit Margin
2.84%
Operating Margin TTM
14.88%
Return On Assets TTM
2.3%
Return On Equity TTM
3.48%
Revenue TTM
6.7B
Revenue Per Share TTM
4.9
Quarterly Revenue Growth YOY
4.1000000000000005%
Gross Profit TTM
2.2B
EBITDA
1.1B
Diluted Eps TTM
0.1
Quarterly Earnings Growth YOY
1.79
EPS Estimate Current Year
0.85
EPS Estimate Next Year
1.19
EPS Estimate Current Quarter
0.16
EPS Estimate Next Quarter
0.23

Analyst Recommendation

Buy
    63%Buy
    22%Hold
    13%Sell
Based on 22 Wall street analysts offering stock ratings for Grifols, S.a.(by analysts ranked 0 to 5 stars)
Based on 22 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
13
17
Hold
5
5
6
Sell
3
3
2

Analyst Forecast

What analysts predicted

Upside of 54.65%

Current $7.74
Target $11.97

Company Financials

FY18Y/Y Change
Revenue
4.5B
↑ 3.91%
Net Income
596.6M
↓ 9.97%
Net Profit Margin
13.3%
↓ 2.05%
FY19Y/Y Change
Revenue
5.1B
↑ 13.64%
Net Income
625.1M
↑ 4.78%
Net Profit Margin
12.26%
↓ 1.04%
FY20Y/Y Change
Revenue
5.3B
↑ 4.73%
Net Income
618.5M
↓ 1.06%
Net Profit Margin
11.58%
↓ 0.68%
FY21Y/Y Change
Revenue
5.6B
↓ 7.62%
Net Income
300.5M
↓ 57.1%
Net Profit Margin
5.38%
↓ 6.2%
FY22Y/Y Change
Revenue
6.5B
↑ 22.92%
Net Income
223.1M
↓ 21.5%
Net Profit Margin
3.43%
↓ 1.95%
FY23Y/Y Change
Revenue
6.6B
↑ 8.71%
Net Income
59.3M
↓ 71.52%
Net Profit Margin
0.9%
↓ 2.53%
Q4 FY22Q/Q Change
Revenue
1.8B
↑ 11.14%
Net Income
21.5M
↓ 54.96%
Net Profit Margin
1.17%
↓ 1.72%
Q1 FY23Q/Q Change
Revenue
1.9B
↑ 0.0%
Net Income
21.9M
↑ 0.0%
Net Profit Margin
1.17%
↑ 0.0%
Q2 FY23Q/Q Change
Revenue
1.8B
↓ 2.88%
Net Income
65.5M
↑ 199.13%
Net Profit Margin
3.61%
↑ 2.44%
Q3 FY23Q/Q Change
Revenue
1.6B
↓ 3.97%
Net Income
59.5M
↓ 0.82%
Net Profit Margin
3.73%
↑ 0.12%
Q4 FY23Q/Q Change
Revenue
1.8B
↑ 10.77%
Net Income
56.0M
↓ 5.96%
Net Profit Margin
3.16%
↓ 0.57%
Q1 FY24Q/Q Change
Revenue
1.8B
↑ 0.0%
Net Income
56.0M
↑ 0.0%
Net Profit Margin
3.16%
↑ 0.0%
FY18Y/Y Change
Total Assets
12.5B
↑ 14.26%
Total Liabilities
7.8B
↑ 6.78%
FY19Y/Y Change
Total Assets
15.5B
↑ 24.57%
Total Liabilities
8.7B
↑ 11.78%
FY20Y/Y Change
Total Assets
15.3B
↓ 1.72%
Total Liabilities
8.6B
↓ 1.63%
FY21Y/Y Change
Total Assets
21.8B
↑ 25.92%
Total Liabilities
12.6B
↑ 29.6%
FY22Y/Y Change
Total Assets
23.1B
↑ 11.96%
Total Liabilities
14.0B
↑ 17.95%
FY23Y/Y Change
Total Assets
21.5B
↓ 0.37%
Total Liabilities
13.5B
↑ 3.0%
Q4 FY22Q/Q Change
Total Assets
22.9B
↓ 0.85%
Total Liabilities
14.1B
↑ 0.76%
Q1 FY23Q/Q Change
Total Assets
21.5B
↑ 0.86%
Total Liabilities
13.1B
↓ 0.75%
Q2 FY23Q/Q Change
Total Assets
23.4B
↓ 0.47%
Total Liabilities
14.4B
↑ 1.02%
Q3 FY23Q/Q Change
Total Assets
22.1B
↑ 2.95%
Total Liabilities
13.5B
↑ 2.17%
Q4 FY23Q/Q Change
Total Assets
21.4B
↓ 2.83%
Total Liabilities
13.5B
↓ 0.2%
Q1 FY24Q/Q Change
Total Assets
21.5B
↑ 0.06%
Total Liabilities
13.5B
↑ 0.0%
FY18Y/Y Change
Operating Cash Flow
737.4M
↓ 12.39%
Investing Cash Flow
-781.9M
↓ 64.23%
Financing Cash Flow
152.5M
↓ 89.37%
FY19Y/Y Change
Operating Cash Flow
568.9M
↓ 22.85%
Investing Cash Flow
-548.8M
↓ 29.81%
Financing Cash Flow
-332.4M
↓ 317.93%
FY20Y/Y Change
Operating Cash Flow
1.1B
↑ 95.16%
Investing Cash Flow
-858.1M
↑ 56.37%
Financing Cash Flow
-354.4M
↑ 6.63%
FY21Y/Y Change
Operating Cash Flow
676.1M
↓ 46.23%
Investing Cash Flow
-33.3M
↓ 96.57%
Financing Cash Flow
1.7B
↓ 515.61%
FY22Y/Y Change
Operating Cash Flow
-11.6M
↓ 101.82%
Investing Cash Flow
-2.1B
↑ 6632.29%
Financing Cash Flow
-185.9M
↓ 111.78%
Q3 FY22Q/Q Change
Operating Cash Flow
-108.0M
↑ 3109.08%
Investing Cash Flow
-37.1M
↓ 95.8%
Financing Cash Flow
56.0M
↓ 112.92%
Q4 FY22Q/Q Change
Operating Cash Flow
-22.7M
↓ 80.71%
Investing Cash Flow
-97.4M
↑ 140.69%
Financing Cash Flow
138.8M
↑ 127.46%
Q1 FY23Q/Q Change
Operating Cash Flow
73.6M
↓ 418.32%
Investing Cash Flow
-134.0M
↑ 35.21%
Financing Cash Flow
220.5M
↑ 56.03%
Q2 FY23Q/Q Change
Operating Cash Flow
-46.1M
↓ 162.65%
Investing Cash Flow
-134.1M
↑ 0.0%
Financing Cash Flow
207.2M
↓ 6.07%
Q3 FY23Q/Q Change
Operating Cash Flow
155.6M
↓ 468.16%
Investing Cash Flow
-122.9M
↑ 0.0%
Financing Cash Flow
-79.4M
↓ 141.79%

Technicals Summary

Sell

Neutral

Buy

Grifols, S.a. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Grifols, S.a.
Grifols, S.a.
11.62%
-2.87%
-23.65%
-48.78%
-65.48%
Eli Lilly And Company
Eli Lilly And Company
-8.88%
28.46%
81.04%
237.65%
658.46%
Johnson & Johnson
Johnson & Johnson
8.73%
0.09%
-7.57%
-7.12%
22.11%
Merck & Co. Inc.
Merck & Co. Inc.
-4.3%
4.16%
17.46%
62.93%
54.55%
Abbvie Inc
Abbvie Inc
6.44%
10.81%
28.38%
54.66%
168.85%
Amgen Inc.
Amgen Inc.
6.87%
7.23%
42.13%
36.4%
90.66%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Grifols, S.a.
Grifols, S.a.
77.3
77.3
0.26
0.85
0.03
0.02
NA
8.75
Eli Lilly And Company
Eli Lilly And Company
129.92
129.92
1.43
13.75
0.51
0.13
0.01
14.23
Johnson & Johnson
Johnson & Johnson
23.93
23.93
0.89
10.01
0.24
0.08
0.03
29.09
Merck & Co. Inc.
Merck & Co. Inc.
141.48
141.48
0.1
8.16
0.05
0.1
0.02
15.94
Abbvie Inc
Abbvie Inc
52.29
52.29
0.45
9.93
0.56
0.08
0.04
4.54
Amgen Inc.
Amgen Inc.
47.88
47.88
2.39
17.96
0.73
0.05
0.03
9.36
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Grifols, S.a.
Grifols, S.a.
Buy
$6.2B
-65.48%
77.3
2.84%
Eli Lilly And Company
Eli Lilly And Company
Buy
$790.8B
658.46%
129.92
17.08%
Johnson & Johnson
Johnson & Johnson
Buy
$376.1B
22.11%
23.93
43.91%
Merck & Co. Inc.
Merck & Co. Inc.
Buy
$318.9B
54.55%
141.48
3.76%
Abbvie Inc
Abbvie Inc
Buy
$311.2B
168.85%
52.29
11.02%
Amgen Inc.
Amgen Inc.
Buy
$180.0B
90.66%
47.88
12.74%

Insights on Grifols, S.a.

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 1.59B → 1.76B (in $), with an average increase of 4.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, 60.03M → 55.99M (in $), with an average decrease of 2.3% per quarter

  • Vs LLY

    In the last 1 year, Eli Lilly And Company has given 81.0% return, outperforming this stock by 104.7%

  • Vs LLY

    In the last 3 years, Eli Lilly And Company has given 237.6% return, outperforming this stock by 286.4%

Institutional Holdings

  • Capital World Investors

    3.06%

  • Brandes Investment Partners & Co

    2.52%

  • Millennium Management LLC

    2.11%

  • Permian Investment Partners

    1.89%

  • Black Creek Investment Management Inc

    1.69%

  • Flat Footed LLC

    1.04%

Corporate Announcements

  • Grifols, S.a. Dividends September,2021

    In the quarter ending September,2021. Grifols, S.a. has declared dividend of $0.46

    Read More

Company Information

for more than 75 years, grifols has been improving the health and well-being of people. our patients are our priority, and our commitment to their health has enabled us to become a global healthcare leader with presence in more than 100 countries. the grifols legacy embodies a spirit of innovation and a forward thinking approach and establish us as an international benchmark in the plasma collection market, the production of plasma derived therapies and transfusion medicine. grifols has three business divisions: bioscience brings together all plasma related activities including research, development, collection, production and sales of life-saving plasma derived therapies. diagnostic provides innovative solutions to support safe and compatible transfusions, monitor therapies, and detect infectious and autoimmune diseases. research novel technologies to further improve treatment outcomes and laboratory efficiency. hospital specializes in non-biological pharmaceutical products. t

Organization
Grifols, S.a.
Employees
23000
CEO
Mr. Thomas H. Glanzmann
Industry
Health Technology

Discover More

FAQs